Intracranial hemorrhage complicating acute myocardial infarction in the era of thrombolytic therapy

Southern Medical Journal

Volumn 90, Issue 1, 1997, Pages 5-12

  Conrad, Arnold R ^a,b   Feffer, Stephen E ^a   Rajan, Raj T ^a   Freeman, Israel ^a  

^a Nassau County Medical Center ^*

^b NASSAU UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; AMINOCAPROIC ACID; ANISTREPLASE; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; FRESH FROZEN PLASMA; HEPARIN; HIRUDIN; PROTAMINE SULFATE; SALICYLIC ACID DERIVATIVE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ACUTE HEART INFARCTION; AGED; BRAIN HEMORRHAGE; CASE REPORT; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRECIPITATE; DISEASE PREDISPOSITION; ELECTROCARDIOGRAM; FIBRINOLYTIC THERAPY; HEPARINIZATION; HUMAN; INFUSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031035351     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-199701000-00002     Document Type: Review

References (61)

1. ISAM Study Group: A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986; 314:1465-1471
2. Guerci AD, Gerstenblith G, Brinker JA, et al: A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med 1987; 317:1613-1618
3. White HD, Norris RM, Brown MA, et al: Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987; 317:850-855
4. Van de Werf F, Arnold FER, for the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator: Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. BMJ 1988; 297:1374-1379
5. Gruppo Italiano per lo Studio della Streptokinasi nell'Infarto Miocardico (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1:397-402
6. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-360
7. Wilcox RG, von der Lippe G, Olsson CG, et al: Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; 2:525-530
8. AIMS Trial Study Group: Long term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet 1990; 335:427-431
9. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994; 343:311-322
10. Fennerty AG, Levine MN, Hirsh J: Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 1989; 95(suppl):88-97
11. Thompson PL, Robinson JS: Stroke after acute myocardial infarction: relation to infarct size. BMJ 1978; 2:457-459
12. Komrad MS, Coffey CE, Coffey KS, et al: Myocardial infarction and stroke. Neurology 1984; 34:1403-1409
13. Asinger RW, Mikell FL, Elsperger J, et al: Incidence of left ventricular thrombosis after acute transmural myocardial infarction. N Engl J Med 1981; 305:297-302
14. Keating EC, Gross SA, Schlamowitz RA, et al: Mural thrombi in myocardial infarctions: prospective evaluation by two-dimensional echocardiography. Am J Med 1983; 74:989-995
15. Weinreich DJ, Burke JF, Pauletto FJ: Left ventricular mural thrombi complicating acute myocardial infarction: long-term follow-up with serial echocardiography. Ann Intern Med 1984; 100:789-794
16. Johannessen KA, Nordrehaug JE, von der Lippe G: Left ventricular thrombosis and cerebrovascular accident in acute myocardial infarction. Br Heart J 1984; 51:553-556
17. Ezekowitz MD, Kellerman DJ, Smith EO, et al: Detection of active left ventricular thrombosis during acute myocardial infarction using indium-III platelet scintigraphy. Chest 1984; 86:35-39
18. Stratton JR, Lighty GW, Pearlman AS, et al: Detection of left ventricular thrombus by two-dimensional echocardiography sensitivity, specificity and causes of uncertainty. Circulation 1982; 66:156-166
19. Visser CA, Kan G, David GK, et al: Two-dimensional echocardiography in the diagnosis of left ventricular thrombus: a prospective study of 67 patients with anatomic validation. Chest 1983; 83:228-232
20. Cairns JA, Hirsh J, Lewis HD, et al: Anti-thrombotic agents in coronary artery disease. Chest 1992; 102(suppl):456-481
21. Haugland JM, Asinger RW, Mikell FL, et al: Embolic potential of left ventricular thrombi detected by two-dimensional echocardiography. Circulation 1984; 70:588-598
22. Visser CA, Kan G, Meltzer RS, et al: Embolic potential of left ventricular thrombus after myocardial infarction: a two-dimensional echocardiographic study of 119 patients. J Am Coll Cardiol 1985; 5:1276-1280
23. Mohr JP: Natural history and pathophysiology of brain infarction. Circulation 1991; 83:1172-1175
24. Maggioni AP, Franzosi MG, Farina ML, et al: Cerebrovascular events after myocardial infarction: analysis of the GISSI trial. BMJ 1991; 302:1428-1431
25. Kennedy JW, Martin GV, Davis KB, et al: The Western Washington intravenous streptokinase in acute myocardial infarction randomized trial. Circulation 1988; 77:345-352
26. TIMI Study Group: Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. N Engl J Med 1989; 320:618-627
27. O'Connor CM, Califf RM, Massey EW, et al: Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis. J Am Coll Cardiol 1990; 16:533-540
28. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico: GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336:65-71
29. The International Study Group: In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336:71-75
30. Maggioni AP, Franzosi MG, Santoro E, et al, Il Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and the International Study Group: The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. N Engl J Med 1992; 327:1-6
31. DeJaegere PP, Arnold AA, Balk AH, et al: Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors. J Am Coll Cardiol 1992; 19:289-294
32. ISIS-3 Collaborative Group: ISIS-3: a randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339:753-770
33. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329:673-682
34. Kase CS, Pessin MS, Zwin JA, et al, and the rt-PA Acute Stroke Study Group: Intracranial hemorrhage following thrombolysis with tissue plasminogen activator (Abstract). Neurology 1990; 40(suppl):191
35. Sloan MA, Plotnick GD: Stroke complicating thrombolytic therapy of acute myocardial infarction (Editorial). J Am Coll Cardiol 1990; 16:541-544
36. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction): guidelines for the early management of patients with acute myocardial infarction. J Am Coll Cardiol 1990; 16:249-292
37. Kase CS: Intracerebral hemorrhage: non-hypertensive causes. Stroke 1986; 17:590-595
38. Vinters HV: Cerebral amyloid angiopathy, a critical review. Stroke 1987; 18:311-324
39. Simoons ML, Maggioni AP, Knatterud G, et al: Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 1993; 342:1523-1528
40. The Heparin-Aspirin Reperfusion Trial (HART) Investigators: A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue-type plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323:1433-1437
41. Bleich SD, Nichols TC, Schumacher RR, et al: Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66:1412-1417
42. The European Cooperative Study Group (ECSG): The effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br Heart J 1992; 67:122-128
43. Antman EM: Hirudin in acute myocardial infarction: safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994; 90:1624-1630
44. GUSTO IIa Investigators: Randomized trial of intravenous heparin versus recombinant hirudin in acute coronary syndromes. Circulation 1994; 90:1631-1637
45. Neuhaus KL, VonEssen R, Tebbe U, et al: Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. Circulation 1994; 90:1638-1642
46. Granger CB, Hirsh J, Califf RM, et al: Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 1996; 93:870-878
47. Grines CL, Brown KF, Marco J, et al, for the Primary Angioplasty in Myocardial Infarction Study Group: A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993; 328:673-679
48. Grines CL, DeMaria AN: Optimal utilization of thrombolytic therapy for acute myocardiol infarction: concepts and controversies. J Am Coll Cardiol 1990; 16:223-231
49. Topol EJ, Califf RM: Thrombolytic therapy for elderly patients (Editorial). N Engl J Med 1992; 327:45-47
50. Kaplan AP, Castellino FJ, Collen D, et al: Molecular mechanisms of fibrinolysis in man. Thromb Haemostas 1978; 39:263-283
51. Francis CW, Marder VJ: Physiologic regulation and pathologic disorders of fibrinolysis. Hum Pathol 1987; 18:263-274
52. Robbins KC, Bernabe P, Arzadon L, et al: The primary structure of human plasminogen. II. The histidine loop of human plasmin:light (B) chains, active center histidine sequence. J Biol Chem 1973; 248:1631-1633
53. Donaldson VH: Effect of plasmin in vitro on clotting factors in plasma. J Lab Clin Med 1960; 56:644-651
54. Fletcher AP, Alkjaersig N, Sherry S: Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (fibrinolytic) states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. J Clin Invest 1962; 41:896-916
55. Marder V, Sherry S: Thrombolytic therapy: current status (first of two parts). N Engl J Med 1988; 318:1512-1520
56. Pool JG, Shannon AE: Production of high-potency concentrates of antihemophilic globulin in a closed-bag system. assay in vitro and in vivo. N Engl J Med 1965; 273:1443-1447
57. Rosenberg RD: Heparin, antithrombin and abnormal clotting. Annu Rev Med 1978; 29:367-378
58. O'Reilly R: Anticoagulant, antithrombotic and thrombolytic drugs. The Pharmacological Basis of Therapeutics. Gilman A, Goodman L, Rall T, et al (eds). New York, Macmillan Publishing Co, 1985, pp 1338-1359
59. Roth GJ, Majerus PW: The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56:624-632
60. Harker LA, Slichter SJ: The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 1972; 287:155-159
61. Eleff SM, Borel C, Bell WR, et al: Acute management of intracranial hemorrhage in patients receiving thrombolytic therapy: case reports. Neurosurgery 1990; 26:867-869